1. Corporate Overview
Dr Robert Scoffin
CEO
http;//www.re-pharm.com rob@re-pharm.com

2. © 2014 Re-Pharm Ltd
> Focus on commercially valuable early stage assets.
> Repositioned compounds
> Using a combination of biological understanding and Cresset tools
> Non Repositioned assets
> Significant value added by appropriate pre-clinical development
> Targeted development to advanced pre-clinical/early clinical
> Combination of Cresset technology and a very experienced team
> Deep re-profiling expertise
> Proven track record – (NVA237 licensed to Novartis)
> Extensive computational chemistry and cheminformatics knowledge
Re-Pharm Summary

3. Cresset Technology

4. © 2014 Re-Pharm Ltd
N
N
Br
F F
F
SH2N
O
O
Condensed representation of electrostatic, hydrophobic
and shape properties (“protein’s view”)
> Molecular Field Extrema (“Field Points”)
Field Points
3D Molecular
Electrostatic
Potential (MEP)
Field Points
= Positive
= Negative
= Shape
= Hydrophobic
2D

5. © 2014 Re-Pharm Ltd
Biologically Relevant Molecular Comparisons
Bioisosteres Bioisosteric groups

6. © 2014 Re-Pharm Ltd
> Virtual screening platform
> Massive cost reduction in wet
screening campaigns
> Library Design
> ‘HTS Rescue’
> Similarity matrices
> Used to compare compounds
for potential re-profiling/side-
effect prediction.
> Applications in ADME/Tox as
well as targeted re-profiling
Cresset Software

7. Introduction

8. © 2014 Re-Pharm Ltd
Reprofiling - Advantages
> Greater knowledge of agent compared to classical NCE discovery
> Existing toxicology, clinical safety, pharmacokinetics
> Lower risk of failure
> Faster development track
> Create and maintain markets through new patents
> Lowered R&D costs
> Orphan indications
> Better profitability
> Commercially Valuable?
> Examples of valuable re-profiled compounds
> Nexium (single enantiomer Omeprazole)
> Advair (combination of Salmeterol & Fluticasone)
> Sildenafil: hypertension to ED
> Raloxifene: Breast Cancer to Osteoporosis
> Milnacipran: antidepressant to fibromyalgia
> NVA 237 – Inhaled Glycopyrronium Bromide for COPD – developed by Arakis/Sosei and
Vectura – licensed to Novartis

9. © 2014 Re-Pharm Ltd
How does Re-Pharm fit?
Target
ID
Pre-Clinical
Development
Early
Clinical
Phase
1 and
POP
Phase II Phase III
Registrati
on
Marketing
Cost
Mid and Major Pharma
• Huge Resources
• Expertise in clinical
development and
approval
Re-Pharm
• Manageable costs
• Expertise in identifying re-
profiling opportunities
• Smart identification of reduced
risk assets

10. © 2014 Re-Pharm Ltd
Management Team & Board
> Rob Scoffin (CEO)
Chemist by training with 23 years experience in developing businesses in the life sciences
and drug discovery services market.
> Alan Rothaul (CSO)
Biologist by training. Over 30 years of drug company experience in major Pharma and
biotech and founding VC based company , Serentis (raised £15M). Experienced in pre-
clinical, clinical and regulatory areas. Has successfully been involved in drug reprofiling
for~15 years and had a key involvement in the identification, development and licencing of
NVA237 to Novartis.
> Andy Vinter (Board)
40 years experience in pharmaceutical R&D, working with major companies and leading
drug discovery groups, including Sir James Black at Smithkline & French.
> David Bardsley (CBO)
Microbiology background and 20 years of commercial experience in a variety of roles
across the life sciences industry.
An experienced management team and Board with an excellent external network

11. RP0217
NON-CONFIDENTIAL

12. © 2014 Re-Pharm Ltd
RP0217 Discovery – example of ‘smart re-profiling’
> Identification of novel target
> Virtual screening using known inhibitor as starting point
> Start with database of known drugs (2,000 compounds)
> Generation of ‘long list’ of candidates for re-profiling (100 compounds)
> Triage the long list by properties, drug-likeness, etc. (50 compounds)
> Triage the long list by ‘medicinal chemistry eyeballing’ (24 compounds)
> Triage compounds by availability (6 compounds)
> Screen using in vitro assay
> Found RP0217 active at nM concentration
12

13. © 2014 Re-Pharm Ltd
Demonstration that RP0217 synergises with Steroids
RP0217 alone
RP0217 + 0.5nM Dex
Selection of minimally
active Dexamethasone
conc. for synergy study
Human Cord Blood Mast Cells
• Selection of minimally active
Dexamethasone
concentration for synergy
study
• Clear synergy with
glucocorticoid ~100 fold left
shift in D/R curve
• Clear anti-inflammatory
activity at very low
concentrations of RP0217 in
combination with steroid
(threshold ~5x10-11 RP0217 +
5x10-10 Dexamethasone)
• Indication of “steroid sparing”
activity-attractive profile for
ocular allergy/inflammation

14. © 2014 Re-Pharm Ltd
RP0217 – suitability as a reprofiled drug
> Old drug (1960’s)
> No S.O.M. patent complications 
> Unexpected and unreported activity for a clinically and
commercially desirable target
> Patentability, accepted target biology 
> Considerable clinical experience (>40 years)
> Comprehensively understood and acceptable safety profile and
pharmacokinetics for both adult and paediatric use by the oral
route
> A highly abridged development path - no need for systemic
toxicology 

15. © 2014 Re-Pharm Ltd
IP and licensing
> Two GB patents filed – April 2013, two PCT applications field as follow-on –
April 2014.
> RPN001/RPN003
> Narrow claims in ophthalmic inflammatory conditions – RP0217 with or without steroids
> RPN002/RPN004
> Broad claims in systemic and topical inflammatory indications – RP0217 and related
compounds, with or without steroids
> Licensing
> Option to licence RP0217 in separate indications
> Topical eye (allergic conjuncto-rhinitis)
> Topical lung (COPD, Asthma, IPF)
> Topical to gut (IBS)
> Would accept single licensee for all above
> Could be enhanced by NCE possibilities as follow on
> Adds systemic indications (Rheumatology, etc)

16. Dr Robert Scoffin Dr Alan Rothaul
Chief Executive Officer Chief Scientific Officer
rob@re-pharm.com alan@re-pharm.com
Dr David Bardsley
Chief Business Officer t: +44 (0)1223 858890
david@re-pharm.com